keyword
MENU ▼
Read by QxMD icon Read
search

neoadjuvant breast

keyword
https://www.readbyqxmd.com/read/28097443/axillary-ultrasound-before-neoadjuvant-chemotherapy-for-breast-cancer-don-t-discount-the-benefits-yet
#1
EDITORIAL
Theresa L Schwartz, Julie A Margenthaler
No abstract text is available yet for this article.
January 17, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28093280/metronomics-in-the-neoadjuvant-and-adjuvant-treatment-of-breast-cancer
#2
Elisabetta Munzone, Marco Colleoni
The concept of metronomic chemotherapy (MC) has evolved from a descriptive preclinical phenomenon encompassing inhibition of angiogenesis to a clinically validated treatment concept involving multiple potential mechanisms of action. Clinicians are progressively more incline to consider MC as a component of mainstream medical oncology practice in advanced breast cancer. However, more recently MC has been tested even in the adjuvant/neoadjuvant setting, taking the opportunity to obtain tumor specimens and blood samples, in order to identify tumor-specific or patient-specific biomarkers for personalizing treatments...
January 13, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28092723/pertuzumab-and-breast-cancer-another-piece-in-the-anti-her2-puzzle
#3
Dr Lorenzo Gerratana, Dr Marta Bonotto, Dr Claudia Bozza, Dr Elena Ongaro, Dr Valentina Fanotto, Dr Giacomo Pelizzari, Prof Fabio Puglisi
The mechanism of action of pertuzumab, a recombinant anti-HER2 humanized monoclonal antibody, is complementary to trastuzumab's. On June 8, 2012, the Food and Drug Administration approved the combination of pertuzumab with trastuzumab and docetaxel as first-line treatment of HER2-positive metastatic breast cancer. Furthermore, pertuzumab is the first drug to be approved in the neoadjuvant setting using a pathological complete response as an endpoint. Areas covered: The review provides insights into the main mechanisms of action of pertuzumab...
January 16, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28089784/axillary-management-of-stage-ii-iii-breast-cancer-patients-treated-with-neoadjuvant-systemic-therapy-results-of-calgb-40601-her2-positive-and-calgb-40603-triple-negative
#4
David W Ollila, Constance T Cirrincione, Donald A Berry, Lisa A Carey, William M Sikov, Clifford A Hudis, Eric P Winer, Mehra Golshan
OBJECTIVES: Management of the axilla in stage II/III breast cancer undergoing neoadjuvant systemic therapy (NST) is controversial. To understand current patterns of care, we collected axillary data from two NST trials: HER2-positive (CALGB40601) and triple-negative (CALGB40603). METHODS: Axillary evaluation pre-/post-NST was per the treating surgeon and could include sentinel node biopsy (SNB). Post-NST, node-positive patients were recommended to undergo axillary lymph node dissection (ALND)...
January 12, 2017: Journal of the American College of Surgeons
https://www.readbyqxmd.com/read/28089283/myc-amplification-as-a-predictive-factor-of-complete-pathologic-response-to-docetaxel-based-neoadjuvant-chemotherapy-for-breast-cancer
#5
Cynthia Brito Lins Pereira, Mariana Ferreira Leal, Eliana Saul Furquim Werneck Abdelhay, Sâmia Demachki, Paulo Pimentel Assumpção, Mirian Carvalho de Souza, Caroline Aquino Moreira-Nunes, Adriana Michiko da Silva Tanaka, Marília Cardoso Smith, Rommel Rodríguez Burbano
BACKGROUND: Neoadjuvant chemotherapy is a standard treatment for stage II and III breast cancer. The identification of biomarkers that may help in the prediction of response to neoadjuvant therapies is necessary for a more precise definition of the best drug or drug combination to induce a better response. MATERIAL AND METHODS: We assessed the role of Ki67, hormone receptors expression, HER2, MYC genes and their protein status, and KRAS codon 12 mutations as predictor factors of pathologic response to anthracycline-cyclophosphamide (AC) followed by taxane docetaxel (T) neoadjuvant chemotherapy (AC+T regimen) in 51 patients with invasive ductal breast cancer...
December 24, 2016: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28088868/prognostic-values-of-ki-67-in-neoadjuvant-setting-for-breast-cancer-a-systematic-review-and-meta-analysis
#6
Lun Li, Dongdong Han, Xiaowei Wang, Quan Wang, Jinhui Tian, Jia Yao, Liqin Yuan, Ke Qian, Qiongyan Zou, Wenjun Yi, Enxiang Zhou, Kehu Yang
AIM: To assess the prognostic values of Ki-67 in neoadjuvant setting for breast cancer patients. METHODS: PubMed and EMBASE were searched. Revman software was used to conduct random-effect model meta-analysis. RESULTS: 49 studies (14,076 patients) were included. High Ki-67 before and after neoadjuvant chemotherapy were associated with worse overall survival (OS; before: hazard ratio [HR]: 2.29; 95% CI: 1.42-3.69; after: HR: 2.24; 95% CI: 1...
January 16, 2017: Future Oncology
https://www.readbyqxmd.com/read/28087643/tumor-brca1-reversion-mutation-arising-during-neoadjuvant-platinum-based-chemotherapy-in-triple-negative-breast-cancer-is-associated-with-therapy-resistance
#7
Anosheh Afghahi, Kirsten M Timms, Shaveta Vinayak, Kristin C Jensen, Allison W Kurian, Robert W Carlson, Pei-Jen Chang, Elizabeth A Schackmann, Anne-Renee Hartman, James M Ford, Melinda L Telli
BACKGROUND: In germline BRCA1 or BRCA2 (BRCA1/2) mutation carriers, restoration of tumor BRCA1/2 function by a secondary mutation is recognized as a mechanism of resistance to platinum and PARP inhibitors, primarily in ovarian cancer. We evaluated this mechanism of resistance in newly diagnosed BRCA1/2-mutant breast cancer patients with poor response to neoadjuvant platinum-based therapy. METHODS: PrECOG 0105 was a phase II neoadjuvant study of gemcitabine, carboplatin and iniparib in patients with stage I-IIIA triple-negative or BRCA1/2 mutation-associated breast cancer (n=80)...
January 13, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28087389/evaluation-of-local-oncologic-safety-in-nipple-areola-complex-sparing-mastectomy-after-primary-chemotherapy-a-propensity-score-matched-study
#8
Roberto Agresti, Marco Sandri, Massimiliano Gennaro, Giulia Bianchi, Ilaria Maugeri, Mario Rampa, Giuseppe Capri, Maria Luisa Carcangiu, Giovanna Trecate, Egidio Riggio, Laura Lozza, Filippo de Braud
BACKGROUND: Nipple-areola complex-sparing mastectomy (NSM), extending the concept of skin-sparing mastectomy, allows for the provision of a better cosmetic result. Large operable T2-T3 breast cancer might theoretically appear suitable for this surgical option as an alternative to conventional mastectomy or breast-conserving surgery, when a good response to primary chemotherapy has been achieved. PATIENTS AND METHODS: From January 2009 to May 2013, 422 patients with invasive breast cancer were progressively accrued to NSM...
December 24, 2016: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28081544/nomogram-to-predict-pathologic-complete-response-in-her2-positive-breast-cancer-treated-with-neoadjuvant-systemic-therapy
#9
Takeo Fujii, Takahiro Kogawa, Jimin Wu, Aysegul A Sahin, Dian D Liu, Mariana Chavez-MacGregor, Sharon H Giordano, Akshara Raghavendra, Rushmy K Murthy, Debu Tripathy, Yu Shen, Jose-Miguel Yamal, Naoto T Ueno
BACKGROUND: Pathologic complete response (pCR) is associated with improved survival outcomes in patients with HER2-positive primary breast cancer. We developed a nomogram to predict the probability of pCR rates by using oestrogen receptor (ER) expression, progesterone receptor (PR) expression and HER2/CEP17 ratio as continuous variables. METHODS: We retrospectively reviewed patients with stages I-III HER2-positive invasive breast cancer who had definitive surgery in 1999-2015 and received neoadjuvant systemic therapy (NST)...
January 12, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28078854/changes-of-expression-of-estrogen-and-progestrone-receptors-human-epithelial-growth-factor-receptor-2-and-ki-67-after-neoadjuvant-chemotherapy-in-the-treatment-of-breast-cancer
#10
M L Li, Y Dong, S L Luan, Z H Zhao, F L Ning
Recent studies suggest that the development and prognosis of breast cancer is in close correlation to molecular subtype of breast cancer. Neoadjuvant chemotherapy has been extensively applied in the treatment of local breast cancer in advanced stage. In order to verify the correlation between expression changes of estrogen receptor, progestrone receptor, human epithelial growth factor receptor 2 and Ki-67 after neoadjuvant chemotherapy and neoadjuvant chemotherapy, we studied 120 patients with stage IIAIIIC breast cancer who underwent neoadjuvant chemotherapy in Binzhou Medical University Hospital, Shandong, China from February 2011 to February 2015...
October 2016: Journal of Biological Regulators and Homeostatic Agents
https://www.readbyqxmd.com/read/28075166/the-predictive-value-of-ki-67-before-neoadjuvant-chemotherapy-for-breast-cancer-a-systematic-review-and-meta-analysis
#11
Xianyu Chen, Chao He, Dongdong Han, Meirong Zhou, Quan Wang, Jinhui Tian, Lun Li, Feng Xu, Enxiang Zhou, Kehu Yang
AIM: To review the predictive values of Ki-67 before neoadjuvant chemotherapy (NAC) for breast cancer patients. METHODS: PubMed and EMBASE were searched. Random-effect model meta-analysis was conducted using Revman software. RESULTS: High Ki-67 was associated with more pathological complete responses (pCRs) events (odds ratio: 3.10; 95% CI: 2.52-3.81; 53 studies, 10,848 patients) regardless of HR(+), HER2(+) and triple-negative breast cancer types, the definitions of pCR and cut-off points for Ki-67...
January 11, 2017: Future Oncology
https://www.readbyqxmd.com/read/28074265/pharmacokinetic-and-exposure-response-analyses-of-pertuzumab-in-combination-with-trastuzumab-and-docetaxel-during-neoadjuvant-treatment-of-her2-%C3%A2-early-breast-cancer
#12
Angelica L Quartino, Hanbin Li, Jin Y Jin, D Russell Wada, Mark C Benyunes, Virginia McNally, Lucia Viganò, Ihsan Nijem, Bert L Lum, Amit Garg
PURPOSE: The NeoSphere trial evaluated pertuzumab in the neoadjuvant setting [early breast cancer (EBC)] with pathological complete response (pCR) as the primary efficacy end point. This analysis of pertuzumab aimed to (1) compare its pharmacokinetics (PK) in patients with EBC versus advanced cancers, (2) to further evaluate PK drug-drug interactions (DDIs) when given in combination with trastuzumab, and (3) to assess the relationship between exposure and efficacy to assess the clinical dosing regimen in the EBC patients...
January 10, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28073896/patient-specific-circulating-tumor-dna-detection-during-neoadjuvant-chemotherapy-in-triple-negative-breast-cancer
#13
Francesca Riva, Francois-Clement Bidard, Alexandre Houy, Adrien Saliou, Jordan Madic, Aurore Rampanou, Caroline Hego, Maud Milder, Paul Cottu, Marie-Paule Sablin, Anne Vincent-Salomon, Olivier Lantz, Marc-Henri Stern, Charlotte Proudhon, Jean-Yves Pierga
BACKGROUND: In nonmetastatic triple-negative breast cancer (TNBC) patients, we investigated whether circulating tumor DNA (ctDNA) detection can reflect the tumor response to neoadjuvant chemotherapy (NCT) and detect minimal residual disease after surgery. METHODS: Ten milliliters of plasma were collected at 4 time points: before NCT; after 1 cycle; before surgery; after surgery. Customized droplet digital PCR (ddPCR) assays were used to track tumor protein p53 (TP53) mutations previously characterized in tumor tissue by massively parallel sequencing...
January 10, 2017: Clinical Chemistry
https://www.readbyqxmd.com/read/28072617/evaluation-of-the-response-to-breast-cancer-neoadjuvant-chemotherapy-using-18f-fdg-positron-emission-mammography-compared-with-whole-body-18f-fdg-pet-a-prospective-observational-study
#14
Mutsumi Noritake, Kazutaka Narui, Tomohiro Kaneta, Sadatoshi Sugae, Kentaro Sakamaki, Tomio Inoue, Takashi Ishikawa
PURPOSE: The aim of this study was to assess therapeutic response to breast cancer neoadjuvant chemotherapy (NAC) by F-FDG positron emission mammography (PEM) compared with that to whole-body F-FDG PET (WBPET). METHODS: Twenty patients underwent WBPET and PEM 3 times: the first time was before NAC, the second time was after 2 courses of NAC, and the third time was after all courses of NAC. A pathological complete response (pCR) was defined as no evidence of residual invasive cancer with or without ductal carcinoma in situ...
January 9, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28071613/clinical-and-pathologic-response-following-taxane-based-neoadjuvant-chemotherapy-in-locally-advanced-breast-cancer-patients-in-a-tertiary-care-centre-in-india
#15
Masillamany Sivasanker, S C Sistla, S Ali Manwar, S Vivekanandam
BACKGROUND: Neoadjuvant chemotherapy has become the standard recommendation in the management of patients with locally advanced breast cancer. At present anthracycline based regimen such as CAF (cyclophosphamide, adriamycin and 5-FU) is widely used in clinical practice. The introduction of taxanes has revolutionized this field because of superior results. AIMS AND OBJECTIVES: This study is designed to compare the efficacy of paclitaxel plus doxorubicin regimen and CAF (cyclophosphamide, doxorubicin and 5-fluorouracil) regimen as neoadjuvant treatment of locally advanced breast cancer and to compare their toxicity profiles and also to correlate the hormonal receptor status in predicting response to the NACT...
April 2016: Indian Journal of Cancer
https://www.readbyqxmd.com/read/28066808/effect-of-mr-imaging-contrast-thresholds-on-prediction-of-neoadjuvant-chemotherapy-response-in-breast-cancer-subtypes-a-subgroup-analysis-of-the-acrin-6657-i-spy-1-trial
#16
Wen Li, Vignesh Arasu, David C Newitt, Ella F Jones, Lisa Wilmes, Jessica Gibbs, John Kornak, Bonnie N Joe, Laura J Esserman, Nola M Hylton
Functional tumor volume (FTV) measurements by dynamic contrast-enhanced magnetic resonance imaging can predict treatment outcomes for women receiving neoadjuvant chemotherapy for breast cancer. Here, we explore whether the contrast thresholds used to define FTV could be adjusted by breast cancer subtype to improve predictive performance. Absolute FTV and percent change in FTV (ΔFTV) at sequential time-points during treatment were calculated and investigated as predictors of pathologic complete response at surgery...
December 2016: Tomography: a Journal for Imaging Research
https://www.readbyqxmd.com/read/28065411/ki67-assessment-in-breast-cancer-an-update
#17
Frederique Penault-Llorca, Nina Radosevic-Robin
Although immunohistochemical detection of the Ki67 antigen has been used for many years to assess cancer proliferation, this marker is still not recommended for routine use in clinical management of breast cancer. The major reason for this situation is a lack of a standardised procedure for Ki67 assessment as well as persistence of several issues of debate with regards to the Ki67 assay interpretation and the marker's clinical utility. Nowadays Ki67 assessment is principally used for estimation of prognosis and guiding the decision on adjuvant treatment choice, as well as for prediction of response to neoadjuvant treatment in ER+/HER2- breast cancer...
January 5, 2017: Pathology
https://www.readbyqxmd.com/read/28065399/oncologic-safety-of-immediate-breast-reconstruction-in-breast-cancer-patients-who-underwent-neoadjuvant-chemotherapy-short-term-outcomes-of-a-matched-case-control-study
#18
Jai Min Ryu, Sungmin Park, Hyun-June Paik, Seok Jin Nam, Seok Won Kim, Se Kyung Lee, Jonghan Yu, Soo Youn Bae, Isaac Kim, Sa Ik Bang, Goo-Hyun Mun, Jai-Kyong Pyon, Byung-Joon Jeon, Jeong Eon Lee
INTRODUCTION: Although the indication for immediate breast reconstruction (IBR) after skin-sparing mastectomy (SSM) or nipple-sparing mastectomy (NSM) has been expanded, IBR after neoadjuvant chemotherapy (NACT) is still controversial. We conducted retrospective matched case-control study to analyze oncologic outcomes between patients who underwent TM only and those who underwent IBR after SSM or NSM after NACT. PATIENTS AND METHODS: A retrospective review of breast cancer patients who underwent IBR after SSM or NSM after NACT between 2008 and 2015 at a single center was conducted...
October 27, 2016: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28064072/long-term-outcome-of-breast-cancer-patients-with-pathologic-n3a-lymph-node-stage
#19
Antonino Grassadonia, Patrizia Vici, Teresa Gamucci, Luca Moscetti, Laura Pizzuti, Lucia Mentuccia, Laura Iezzi, Maria Teresa Scognamiglio, Marinella Zilli, Jamara Giampietro, Vincenzo Graziano, Clara Natoli, Nicola Tinari
PURPOSE: To evaluate factors influencing the long-term outcome of patients presenting with 10 or more metastatic axillary lymph nodes (pN3a) after surgery for primary breast cancer. METHOD: Between January 1990 and December 2015, a total of 130 patients with pN3a breast cancer at surgery were identified in our Institutions and included in the study. Twenty-nine of them (22.3%) received neoadjuvant chemotherapy. The Multivariate Cox proportional hazards model was used to determine independent prognostic factors associated with DFS and OS...
January 5, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28063331/pcr-rates-in-patients-with-bilateral-breast-cancer-after-neoadjuvant-anthracycline-taxane-based-chemotherapy-a-retrospective-pooled-analysis-of-individual-patients-data-of-four-german-neoadjuvant-trials
#20
Mattea Reinisch, Jens Huober, Gunter von Minckwitz, Jens-Uwe Blohmer, Carsten Denkert, Claus Hanusch, Christian Jackisch, Sherko Kümmel, Andreas Schneeweiss, Kerstin Rhiem, Bianca Lederer, Michael Untch, Valentina Nekljudova V, Sibylle Loibl
PURPOSE: Patients with bilateral breast cancer (BBC) are usually excluded from participating in clinical trials and little is known about the response and outcome of BBC to neoadjuvant chemotherapy compared to unilateral BC (UBC). METHODS: We prospectively captured the information on patients with BBC in our database treated within four neoadjuvant chemotherapy trials and collected retrospectively the rate of pathological complete response (pCR) defined as ypT0 ypN0, ypT0/is ypN0, ypT0 ypNX, clinical and histologic parameters...
January 4, 2017: Breast: Official Journal of the European Society of Mastology
keyword
keyword
72735
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"